| 氯吡格雷抵抗研究现状 |
| |
| 引用本文： | 林运灵,陈良龙. 氯吡格雷抵抗研究现状[J]. 心血管病学进展, 2007, 28(4): 550-554 |
| |
| 作者姓名： | 林运灵 陈良龙 |
| |
| 作者单位： | 福建医科大学附属协和医院心内科,福建,福州,350001 |
| |
| 摘 要： | 氯吡格雷对血小板的抑制作用具有个体差异性。氯吡格雷抵抗是指那些接受了标准的抗血小板治疗的病人仍然发生不良的心血管事件。导致氯吡格雷抵抗的原因是多方面的,主要有P2Y12受体及CYP3A的基因多态性、药物吸收及活性代谢物清除的个体差异、血小板高反应性等。目前对氯吡格雷抵抗仍然缺乏统一的标准,正确认识、发现、解决氯吡格雷抵抗需要更深入的研究。
|
| 关 键 词： | 氯吡格雷 药物抵抗 血小板聚集 |
| 文章编号： | 1004-3934（2007）04-0550-05 |
| 修稿时间： | 2006-07-132006-09-04 |
Clopidogrel Resistance |
| |
| LIN Yun-ling,CHEN Liang-long. Clopidogrel Resistance[J]. Advances in Cardiovascular Diseases, 2007, 28(4): 550-554 |
| |
| Authors: | LIN Yun-ling CHEN Liang-long |
| |
| Affiliation: | Department of Cardiology, The Affiliated Union Hospital of Fujian Medical University, Fuzhou 350001, China |
| |
| Abstract: | Clopidogrel-induced platelet inhibition is patient-specific. Its antiplatelet effect is not uniform in all patients. Clopidogrel resistance illustrates that cardiovascular events still occur in those patients who are taking standard-dose clopidogrel therapy. There is currently no consensus as to what exactly constitutes clopidogrel resistance. The interpatient variability in clopidogrel response is multifactorial. The possible mechanisms include genetic polymorphisms of the P2Y12 receptor and of the CYP3As, variable absorption of the prodrug, or clearance of the active metabolite, or platelet high sensitivity. Further study is needed of clopidogrel resistance. |
| |
| Keywords: | clopidogrel drug resistance platelet aggregation |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
